Substitution at the F-Ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities

Journal of Medicinal Chemistry

Volumn 42, Issue 15, 1999, Pages 2927-2935

  Bailly, Christian ^a   Qu, Xiaogang ^b   Chaires, Jonathan B ^b   Colson, Pierre ^c   Houssier, Claude ^c   Ohkubo, Mitsuru ^d   Nishimura, Susumu ^d   Yoshinari, Tomoko ^d  

^a INSERM   (France)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; 6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A][PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; ANTINEOPLASTIC AGENT; BE 13793C; CAMPTOTHECIN; CELL DNA; DAUNORUBICIN; DNA TOPOISOMERASE; DOXORUBICIN; ED 110; INDOLOCARBAZOLE DERIVATIVE; REBECCAMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CONFORMATION; DRUG DNA BINDING; ENZYME INHIBITOR INTERACTION; HUMAN; HUMAN CELL; INTERCALATION COMPLEX; MOLECULAR INTERACTION; MOLECULAR STABILITY; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBAZOLES; CATTLE; CIRCULAR DICHROISM; DNA; DNA TOPOISOMERASES, TYPE I; DNA, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; GLUCOSIDES; HUMANS; INHIBITORY CONCENTRATION 50; INTERCALATING AGENTS; SEQUENCE ANALYSIS, DNA; SPECTROMETRY, FLUORESCENCE; SPECTROPHOTOMETRY, ULTRAVIOLET; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0033614922     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990108t     Document Type: Article

References (45)

1. Kojiri, K.; Kondo, H.; Yoshinari, T.; Arakawa, H.; Nakajima, S.; Satoh, F.; Kawamura, K.; Okura, A.; Suda, H.; Okanishi, M. A new antitumor substance BE-13793C, produced by a streptomycete. Taxonomy, fermentation, isolation, structure determination and biological activity. J. Antibiot. 1991, 44, 723-728.
2. Tanaka, S.; Ohkubo, M.; Kojiri, K.; Suda, H.; Yamada, A.; Uemura, D. A new indolopyrrolocarbazole antitumor substance, ED-110, a derivative of BE-13793C. J. Antibiot. 1992, 45, 1797-1798.
3. Yoshinari, T.; Yamada, A.; Uemura, D.; Nomura, K.; Arakawa, H.; Kojiri, K.; Yoshida, E.; Suda, H.; Okura, A. Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110. Cancer Res. 1993, 53, 490-494.
4. Arakawa, H.; Iguchi, T.; Yoshinari, T.; Kojiri, K.; Suda, H.; Okura, A. ED-110, a novel indolocarbazole, prevents the growth of experimental tumors in mice. Jpn. J. Cancer Res. 1993, 53, 574-581.
5. Arakawa, H.; Iguchi, T.; Morita, M.; Yoshinari, T.; Kojiri, K.; Suda, H.; Okura, A.; Nishimura, S. Novel indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosyl)-5H- indolo[2,3-a]pyrrolo-[3,4-c]carbazole-5,7-(6H)-dione (NB-506): its potent antitumor activities in mice. Cancer Res. 1995, 55, 1316-1320.
6. Arakawa, H.; Matsumoto, H.; Monta, M.; Sasaki, M.; Taguchi, K.; Okura, A.; Nishimura, S. Antimetastatic effect of a novel indolocarbazole (NB-506) on IMC-HM marine tumor cells metastasized to the liver. Jpn. J. Cancer Res. 1996, 56, 518-523.
7. Ohe, Y.; Tanigawara, Y.; Fujii, H.; Ohtsu, T.; Wakita, H.; Igarashi, T.; Minami, H.; Eguchi, K.; Shinkai, T.; Tamura, T.; Kunotoh, H.; Saijo, N.; Okada, K.; Ogino, H.; Sasaki, Y. Phase I and pharmacology study of 5-day infusion of NB-506. Proc. ACSO 1997, 16, 199a.
8. Saijo, N. New chemotherapeutic agents for the treatment of nonsmall cell lung cancer. Chest 1998, 113, 17S-23S.
9. Yamashita, Y.; Fujii, N.; Murakata, C.; Ashizawa, T.; Okabe, M.; Nakano, H. Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry 1992, 31, 12069-12075.
10. Kanzawa, F.; Nishio, K.; Kubota, N.; Saijo, N. Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB. Cancer Res. 1995, 55, 2806-2813.
11. Vanhoefer, U.; Voigt, W.; Hilger, R. A.; Yin, M.-B.; Harstrick, A.; Seeber, S.; Rustum, Y. M. Cellular determinants of resistance to indolocarbazole analogue NB-506. A novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells. Oncol. Res. 1997, 9, 485-494.
12. Yoshinari, T.; Matsumoto, M.; Arakawa, H.; Okada, H.; Noguchi, K.; Suda, H.; Okura, A.; Nishimura, S. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosyl)-5H- indolo[2,3-a]pyrrolo-[3,4-c]-carbazole-5,7-(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity. Cancer Res. 1993, 55, 1310-1315.
13. Pommier, Y.; Pourquier, P.; Fan, Y.; Strumberg, D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta 1998, 1400, 83-106.
14. Pommier, Y. Diversity of DNA topoisomerases I and inhibitors. Biochimie 1998, 80, 255-270.
15. Bailly, C. Topoisomerase I poisons and suppressors as anticancer drugs. Curr. Med. Chem. 1999, in press.
16. Rodrigues-Pereira E.; Belin, L.; Sancelme, M.; Prudhomme, M.; Ollier, M.; Rapp, M.; Servère, D.; Riou; J.-F.; Fabbro, D. Structure-activity relationships in a series of substituted indolocarbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties. J. Med. Chem. 1996, 39, 4471-4477.
17. Anizon, F.; Belin, L.; Moreau, P.; Sancelme, M.; Voldoire, A.; Prudhomme, M.; Ollier, M.; Sevère, D.; Riou, J.-F.; Bailly, C.; Fabbro, D.; Meyer, T. Syntheses and biological activity (topoisomerases inhibition, antitumoral and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group. J. Med. Chem. 1997, 40, 3456-3465.
18. Anizon, F.; Moreau, P.; Sancelme, M.; Voldoire, A.; Prudhomme, M.; Ollier, M.; Sevère, D.; Riou, J.-F.; Bailly, C.; Fabbro, D.; Meyer, T.; Aubertin, A.-M. Syntheses, biochemical and biological evaluation of staurosporine analogues from the microbial metabolite rebeccamycin. BioOrg. Med. Chem. 1998, 66, 1597-1604.
19. Moreau, P.; Anizon, F.; Sancelme, M.; Prudhomme, M.; Bailly, C.; Carrasco, C.; Ollier, M.; Sevère, D.; Riou, J.-F.; Fabro, D.; Meyer, T.; Aubertin, A.-M. Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle. J. Med. Chem. 1998, 41, 1631-1640.
20. Moreau, P.; Anizon, F.; Sancelme, M.; Prudhomme, M.; Bailly, C.; Ollier, M.; Sevère, D.; Riou, J.-F.; Fabbro, D.; Meyer, T.; Aubertin, A.-M. Syntheses and biological activities of rebeccamycin analogues. Introduction of a halogenoacetyl substituent. J. Med. Chem. 1999, 42, 584-592.
21. Bailly, C.; Qu, X.; Anizon, F.; Prudhomme, M.; Riou, J. F.; Chaires, J. B. Enhanced binding to DNA and topoisomerase I inhibition by an analogue of the antitumor antibiotic rebeccamycin containing an amino-sugar residue. Mol. Pharmacol. 1999, 55, 377-385.
22. Bailly, C.; Riou, J.-F.; Colson, P.; Houssier, C.; Rodrigues-Pereira, E.; Prudhomme, M. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin. Biochemistry 1997, 36, 3917-3929.
23. Bailly, C.; Qu, X.; Graves, D. E.; Prudhomme, M.; Chaires, J. B. Calories from carbohydrates. Energetic contribution of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibition. Chem. Biol. 1999, 6, 277-286.
24. Friedman, R. A.; Manning, G. S. Polyelectrolyte effects on site-binding equilibria with application to the intercalation of drugs into DNA. Biopolymers 1984, 23, 2671-2714.
25. Record, M. T.; Anderson, C. F.; Lohman, T. M. Thermodynamic analysis of ion effects on the binding and conformational equilibria of proteins and nucleic acids: the role of ion association or release, screening, and ion effects on water activity. Q. Rev. Biophys. 1978, 11, 103-178.
26. Chaires, J. B. Dissecting the free energy of drug binding to DNA. Anticancer Drug Des. 1996, 11, 569-580.
27. Bailly, C.; Hénichart, J.-P.; Colson, P.; Houssier, C. Drug-DNA sequence-dependent interactions analysed by electric linear dichroism. J. Mol. Recognit. 1992, 5, 155-171.
28. Goodisman, J.; Dabrowiak, J. C. Structural changes and enhancements in DNase I footprinting experiments. Biochemistry 1992, 31, 1058-1064.
29. Bailly, C.; Colson, P.; Houssier, C.; Rodrigues-Pereira, E.; Prudhomme, M.; Waring, M. J. Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin. Mol. Pharmacol. 1998, 53, 77-87.
30. Labourier, E.; Riou, J. F.; Prudhomme, M.; Carrasco, C.; Bailly, C.; Tazi, J. Poisoning of topoisomerase I by an antitumor indolocarbazole drug: stabilization of topoisomerase I-DNA covalent complexes and specific inhibition of the protein kinase activity. Cancer Res. 1999, 59, 52-55.
31. Fukasawa, K.; Komatani, H.; Hara, Y.; Suda, H.; Okura, A.; Nishimura, S.; Yoshinari, T. Sequence-selective cleavage by a topoisomerase I poison, NB-506. Int. J. Cancer 1998, 75, 145-150.
32. Larsen, A. K.; Grondard, L.; Couprie, J.; Desoize, B.; Comoe, L.; Jardillier, J. C.; Riou, J. F. The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II. Biochem. Pharmacol. 1993, 46, 1403-1412.
33. Weitman, S.; Moore, R.; Barrera, H.; Cheung, N. K.; Izbicka, E.; Von Hoff, D. D. In vitro antitumor activity of rebeccamycin analogue NSC655649 against pediatric solid tumors. J. Pediatr. Hematol. Oncol. 1998, 20, 136-139.
34. Ohkubo, M.; Kawamoto, H.; Ohno, T.; Nakano, M.; Morishima, H. Synthesis of NB-506, a new anticancer agent. Tetrahedron 1997, 53, 585-592.
35. Ohkubo, M.; Nishimura, T.; Jona, H.; Honma, T.; Morishima, H. Practical synthesis of indolopyryrrolocarbazoles. Tetrahedron 1996, 52, 8099-8112.
36. Ohkubo, M.; Nishimura, T.; Jona, H.; Honma, T.; Ito, S.; Morishima, H. Synthesis of dissymmetric indolocarbazole glycosides using the Mitsunobu reaction at the glycosylation step. Tetrahedron 1997, 53, 5937-5950.
37. Wells, R. D.; Larson, J. E.; Grant, R. C.; Shortle, B. E.; Cantor, C. R. Physicochemical studies on polydeoxyribonucleotides containing defined repeating nucleotide sequences. J. Mol. Biol. 1970, 54, 465-497.
38. Chaires, J. B.; Satyanarayana, S.; Suh, D.; Fokt, I.; Przewloka, T.; Priebe, W. Parsing the free energy of anthracycline antibiotic binding to DNA. Biochemistry 1996, 35, 2047-2053.
39. Houssier, C.; O'Konski, C. T. Electro-optical instrumentation systems with their data acquisiton and treatment. In Molecular Electro-optics; Krause, S., Ed.; Plenum Publishing Corporation: New York, 1981; pp 309-339.
40. Houssier, C. Investigating nucleic acids, nucleoproteins, polynucleotides, and their interactions with small ligands by electro-optical systems. In Molecular Electro-optics; Krause, S., Ed.; Plenum Publishing Corporation: New York, 1981; pp 363-398.
41. Colson, P.; Bailly, C.; Houssier, C. Electric linear dichroism as a new tool to study sequence preference in drug binding to DNA. Biophys. Chem. 1996, 58, 125-140.
42. Bailly, C.; Waring, M. J. Comparison of different footprinting methodologies for detecting binding sites for a small ligand on DNA. J. Biomol. Struct. Dyn. 1995, 12, 869-898.
43. Drew, H. R.; Weeks, J. R.; Travers, A. A. Negative supercoiling induces spontaneous unwinding of bacterial promoter. EMBO J. 1985, 4, 1025-1032.
44. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; MaMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112.
45. Rubinstein, L. V.; Shoemaker, R. H.; Paull, K. D.; Simon, R. M.; Tosini, S.; Skehan, P.; Scudiero, D. A.; Monks, A.; Boyd, M. R. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against diverse panel of human tumor cell lines. J. Natl. Cancer Inst. 1990, 82, 1113-1118.